These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

64 related articles for article (PubMed ID: 8892744)

  • 41. Amifostine in the treatment of low-risk myelodysplastic syndromes.
    Grossi A; Fabbri A; Santini V; Leoni F; Nozzoli C; Longo G; Pagliai G; Ciolli S; Rossi Ferrini P
    Haematologica; 2000 Apr; 85(4):367-71. PubMed ID: 10756361
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Usefulness of immature platelet fraction for the clinical evaluation of myelodysplastic syndromes.
    Saigo K; Takenokuchi M; Imai J; Numata K; Isono S; Zenibayashi M; Tanioka H; Yoshioka T; Nishizawa A; Takada M; Nomura T; Kubota Y
    Lab Hematol; 2009; 15(2):13-6. PubMed ID: 19561008
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Results of topotecan-based combination therapy in patients with myelodysplastic syndromes and chronic myelomonocytic leukemia.
    Beran M; Kantarjian H
    Semin Hematol; 1999 Oct; 36(4 Suppl 8):3-10. PubMed ID: 10622223
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Platelet counts and haemorrhagic diathesis in patients with myelodysplastic syndromes.
    Neukirchen J; Blum S; Kuendgen A; Strupp C; Aivado M; Haas R; Aul C; Gattermann N; Germing U
    Eur J Haematol; 2009 Nov; 83(5):477-82. PubMed ID: 19548919
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Cerebral mucormycosis in a patient with myelodysplastic syndrome taking corticosteroids.
    Droll A; Kunz F; Passweg JR; Michot M
    Br J Haematol; 2004 Aug; 126(4):441. PubMed ID: 15287935
    [No Abstract]   [Full Text] [Related]  

  • 46. 13-cis-retinoic acid in myelodysplastic syndromes.
    Greenberg BR; Buzaid AC; Meyskens FL
    J Clin Oncol; 1986 Aug; 4(8):1282. PubMed ID: 3525772
    [No Abstract]   [Full Text] [Related]  

  • 47. [Hemorheologic study in myelodysplastic syndrome].
    Rohrberg R; Sternitzky R
    Folia Haematol Int Mag Klin Morphol Blutforsch; 1989; 116(1):75-80. PubMed ID: 2472331
    [No Abstract]   [Full Text] [Related]  

  • 48. Vitamin K2 therapy for a patient with myelodysplastic syndrome.
    Yaguchi M; Miyazawa K; Otawa M; Ito Y; Kawanishi Y; Toyama K
    Leukemia; 1999 Jan; 13(1):144-5. PubMed ID: 10049052
    [No Abstract]   [Full Text] [Related]  

  • 49. Sustained haematological response to high-dose oral alfacalcidol in patients with myelodysplastic syndromes.
    Kelsey SM; Newland AC; Cunningham J; Makin HL; Coldwell RD; Mills MJ; Grant IR
    Lancet; 1992 Aug; 340(8814):316-7. PubMed ID: 1353239
    [No Abstract]   [Full Text] [Related]  

  • 50. [Neonatal hypocalcemia. Treatment with 25-hydroxyvitamin D3].
    Alix D; Riche C; Caroff J
    Arch Fr Pediatr; 1981 Jan; 38(1):69. PubMed ID: 7224802
    [No Abstract]   [Full Text] [Related]  

  • 51. Clarifications to the standard neutrophil response criteria for clinical trials in myelodysplastic syndromes are needed.
    Steensma DP; Letendre L; Tefferi A
    Blood; 2001 May; 97(10):3321-2. PubMed ID: 11368066
    [No Abstract]   [Full Text] [Related]  

  • 52. An under-recognized cause of copper deficiency mimicking myelodysplastic syndrome.
    Stafford MA; Lim MY
    Ann Hematol; 2019 Apr; 98(4):1021-1023. PubMed ID: 30357463
    [No Abstract]   [Full Text] [Related]  

  • 53. Danazol therapy in myelodysplastic syndromes.
    Pozzato G; Franzin F; Moretti M; Campanacci L
    Haematologica; 1992; 77(1):96. PubMed ID: 1398293
    [No Abstract]   [Full Text] [Related]  

  • 54. [ Myelodysplastic syndrome].
    Fenaux P
    Rev Prat; 2002 Dec; 52(20):2301-8. PubMed ID: 12621953
    [No Abstract]   [Full Text] [Related]  

  • 55. Hematologic benefits of 1-hydroxyvitamin D3 in an elderly patient with chronic myelodysplastic syndrome.
    Motomura S; Fujisawa S; Tsunooka S; Fujimaki K; Mohri H; Okubo T
    Am J Hematol; 1996 Oct; 53(2):143-4. PubMed ID: 8892744
    [No Abstract]   [Full Text] [Related]  

  • 56. Effect of low-dose 1-hydroxyvitamin D3 in a patient with myelodysplasia after induction therapy for acute myelocytic leukemia.
    Fujisawa S; Motomura S; Sakai R; Tomita N; Fujimaki K; Mohri H; Okubo T
    Anticancer Drugs; 1997 Jun; 8(5):466-7. PubMed ID: 9215609
    [No Abstract]   [Full Text] [Related]  

  • 57. [Treatment of myelodysplastic syndrome and acute myelogenous leukemia with vitamin D3 (1 alpha(OH)D3)].
    Taoka T; Hamamoto T; Okuda Y; Hata Y; Kubota Y; Tanaka T; Irino S; Miyazaki T; Ohbayashi S
    Rinsho Ketsueki; 1987 Jun; 28(6):830-8. PubMed ID: 3478504
    [No Abstract]   [Full Text] [Related]  

  • 58.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 59.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 60.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.